Update on strongyloidiasis in the immunocompromised host

被引:105
作者
Marcos L.A. [1 ,2 ]
Terashima A. [2 ,3 ]
Canales M. [2 ,3 ]
Gotuzzo E. [2 ,3 ]
机构
[1] Internal Medicine Department, School of Medicine, Washington University, St. Louis, MO 63110
[2] Institute of Tropical Medicine Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima
[3] Lima 100
关键词
Agar plate; Anthelminthic; Autoinfection; Dissemination; Hyperinfection syndrome; Immigrant; Immunocompromised host; Ivermectin; Parenteral; Strongyloides stercoralis; Strongyloidiasis; Transplant population; USA;
D O I
10.1007/s11908-010-0150-z
中图分类号
学科分类号
摘要
Immunocompromised persons are the most vulnerable population at risk for developing life-threatening clinical syndromes associated with strongyloidiasis, such as hyperinfection syndrome (HS) or dissemination. This review focuses on describing Strongyloides infection in the immunocompromised host, including immune response against this infection, analyzing the cases with HS published during the past 4 years in the United States, and describing the most sensitive diagnostic tools and the most effective treatment for each clinical syndrome. Strongyloidiasis is becoming an important parasitic disease in the United States, especially in the immunocompromised immigrant population. Because the transplant population is particularly at risk for developing HS, both recipients and donors should be screened for Strongyloides. Clinicians should also be aware that the development of HS can follow unexpectedly a few days after appropriate anthelminthic therapy. Highly sensitive screening tests are still not available in the major tertiary medical centers. Parenteral ivermectin has been used in some severe cases. Further therapy developments and improving diagnostic tools are warranted. © 2010 Springer Science+Business Media, LLC.
引用
收藏
页码:35 / 46
页数:11
相关论文
共 113 条
  • [91] Datry A., Hilmarsdottir I., Mayorga-Sagastume R., Lyagoubi M., Gaxotte P., Biligui S., Chodakewitz J., Neu D., Danis M., Gentilini M., Treatment of Strongyloides stercoralis infection with ivermectin compared with albendazole: Results of an open study of 60 cases, Transactions of the Royal Society of Tropical Medicine and Hygiene, 88, 3, pp. 344-345, (1994)
  • [92] Marti H., Haji H.J., Savioli L., Et al., A comparative trial of a single-dose ivermectin versus three days of albendazole for treatment of Strongyloides stercoralis and other soil-transmitted helminth infections in children, Am. J. Trop. Med. Hyg., 55, pp. 477-481, (1996)
  • [93] Alvarez H., Terashima A., Nematodiosis and Strongyloidosis, Diagnostico, 39, pp. 112-115, (2000)
  • [94] Terashima A., Parasitosis, Topicos Selectos en Medicina Interna, Gastroenterologia, Tubo Digestivo, Higado, Pancreas y Vias Biliares, (2006)
  • [95] Gupta S., Jain A., Fanning T.V., Couriel D.R., Jimenez C.A., Eapen G.A., An unusual cause of alveolar hemorrhage post hematopoietic stem cell transplantation: A case report, BMC Cancer, 6, (2006)
  • [96] Hunter C.J., Petrosyan M., Asch M., Dissemination of strongyloides stercoralis in a patient with systemic lupus erythematosus after initiation of albendazole: A case report, Journal of Medical Case Reports, 2, (2008)
  • [97] Marty F.M., Lowry C.M., Rodriguez M., Et al., Treatment of human disseminated strongyloidiasis with a parenteral veterinary formulation of ivermectin, CID, 41, (2005)
  • [98] Satou T., Koga M., Koike K., Tada I., Nikaido T., Nematocidal activities of thiabendazole and ivermectin against the larvae of Strongyloides ratti and S. venezuelensis, Veterinary Parasitology, 99, 4, pp. 311-322, (2001)
  • [99] Satou T., Koga M., Matsuhashi R., Et al, Assay of Nematocidal Activity of Isoquinoline Alkaloids Using Third Stage Larvae of Strongyloides Ratti and S. Venezuelensis. Vet Parasitol, 104, pp. 131-138, (2002)
  • [100] Tarr P.E., Miele P.S., Peregoy K.S., Et al., Case report: Rectal adminstration of ivermectin to a patient with Strongyloides hyperinfection syndrome, Am J Trop Med Hyg., 68, pp. 453-455, (2003)